Peer-reviewed article
ATRT-16. MODELLING ATRT THROUGH SWI/SNF COMPLEX DEFICIENCY IN GENETICALLY-ENGINEERED MOUSE MODELS
Bondoc A, Golbourn B, Smith C, Huang A, Rutka J ·
Summary
Written by AI, not yet AICS's view · claude-haiku-4-5-20251001This is a basic science study using genetically-engineered mouse models to understand how loss of the smarcb1 gene leads to atypical teratoid/rhabdoid tumours (ATRT), a rare childhood brain cancer. Researchers used conditional knockout techniques to remove smarcb1 in different brain cell types and developmental stages. The findings show that the timing and location of gene loss determines whether tumours develop and what form they take.
Key points
- Loss of smarcb1 in developing neural cells caused severe neurological defects with median 12-day survival in mice
- Targeted smarcb1 loss in later embryonic stages (BLBP-expressing cells) did not produce tumours, but widespread loss at embryonic day 6.5 did
- Isolated neural stem/progenitor cells with smarcb1 loss showed decreased proliferation and increased cell death rather than tumour growth
- The study generated a mouse model that produces multiple distinct tumour types similar to human ATRT
Limitations
This is a laboratory study in mice and does not evaluate any intervention for children or provide evidence about child health outcomes. The findings are mechanistic and preclinical, requiring translation to clinical applications.
Abstract
Abstract Atypical Teratoid/Rhabdoid Tumours (ATRT) are highly malignant neoplasms arising primarily in the CNS of children. They are defined by loss of function mutations in smarcb1, a gene serving a vital role in neurogenesis and differentiation. In order to recapitulate ATRT in the mouse, we used a Cre-Lox recombination system to conditionally knockout smarcb1 in specific cell compartments. Loss of smarcb1 in BLBP-expressing cells of the developing brain led to severe neurologic defects. Mice exhibited seizures, ataxia, and median 12-day survival. Histological analysis revealed severe thinning of the cerebral cortex and cerebellum. Temporally-targeted smarcb1 loss in BLBP/Nestin-expressing embryonic compartments did not result in tumour formation. Similarly, BLBP-expressing, smarcb1-deficient neural stem/progenitor cells (NSC/NPCs) were isolated and allografted but did not form tumours. These cells demonstrated decreased proliferation, higher apoptosis, and upregulation of p53, CDKN1A, and CDKN2A. In contrast, ubiquitous smarcb1 loss at the earlier embryonic day 6.5 produced widespread tumorigenicity in the forebrain, hindbrain, skullbase, and spine; each with unique phenotypes, survival, and morphology. We employed a clinically-relevant Nanostring gene-panel screen to stratify tumours into genetically distinct subgroups. Our findings indicate that smarcb1 plays an important role in CNS development. Loss of smarcb1 in NSC/NPCs is lethal, and its developmental context influences cell fate. Targeted smarcb1 loss likely plays a tumorigenic role at an earlier developmental stage than previously determined, in a diverse array of primitive stem cells. These data support the generation of a murine ATRT model capable of producing distinct tumour entities that recapitulate the human disease.